This extraction is sourced from Myriad Genetics' 8-K exhibit (Exhibit 99.1) filed with the SEC on October 20, 2026, carrying the joint press release announcing the signed agreement. The deal remained subject to regulatory clearance and customary closing conditions as of this filing, with Myriad stating it would provide further commentary on its third-quarter earnings call scheduled for November 4, 2026.
Barclays acted as financial advisor to Labcorp, the acquirer, while Guggenheim Securities, LLC acted as exclusive financial advisor to Myriad Genetics, the seller. Guggenheim's engagement was explicitly described as exclusive, while Barclays' role for Labcorp was not qualified as exclusive or lead in the release.
On the legal side, Covington & Burling LLP served as legal advisor to Myriad Genetics, while Polsinelli served as legal advisor to Labcorp.
The transaction is an all-cash divestiture of a discrete business unit rather than a sale of Myriad as a whole. Over the trailing twelve months, Myriad's Prenatal Health portfolio had been used by thousands of providers and over 600,000 patients. Labcorp expects the deal to be slightly accretive to adjusted earnings in its first year and to reach average diagnostics segment margins by the end of year two once integrated. The transaction is expected to close by early 2027.
The press release does not disclose the value of the inventory component being added to the $210 million cash price, nor does it disclose advisory fees paid to either Barclays or Guggenheim Securities, or any termination fee terms in the definitive agreement.